A single-center study found that giving hematopoietic stem cell transplant (HSCT) recipients preventive doses of oral vancomycin was associated with a significant decrease in the risk of Clostridioides difficile infection (CDI), researchers reported today in Antimicrobial Stewardship & Healthcare Epidemiology.
Because of their immunocompromised state, HSCT patients have a nine-fold increased risk of CDI compared with the general population. To reduce this risk, the bone marrow transplant team at Robert Wood Johnson University Hospital (RWJUH) in New Jersey implemented a protocol in December 2019 for universal oral vancomycin prophylaxis (OVP) for all patients undergoing HSCT. Prior to this protocol, the decision to use OVP was made by the provider and was not routine.
To assess the effectiveness of the OVP protocol, researchers with RWJUH and Rutgers University reviewed the medical records of all HSCT patients admitted from January 2015 through August 2022. The primary end point was the incidence of in-hospital CDI. Secondary endpoints included incidence of vancomycin-resistant enterococci (VRE) and gram-negative bloodstream infections, hospital survival, and length of hospital stay.
Promising results, but clinical trials needed
A total of 156 HSCT patients met inclusion criteria, with 75 in the pre-universal prophylaxis era (no OVP) and 81 in the post-universal prophylaxis era (OVP). The most common indicators for transplant were multiple myeloma, acute myeloid leukemia, and Hodgkin lymphoma. Among the 81 patients in the OVP group, there was 1 (1.23%) case of CDI, compared with 8 (10.67%) of 75 in the no OVP group. No positive VRE cultures were found in either group. There were no significant between-group differences in the incidence of gram-negative bloodstream infections, hospital survival, and length of stay.
"These findings are promising considering infections such as CDI are among the most common complications affecting HSCT patients," the study authors wrote. But they caution that more research is needed to better understand the potential implications of using OVP on HSCT patients' enteric microbiota, increased VRE colonization, and the risk of the emergence of vancomycin-resistant C difficile strains.
"Prospective clinical trials and cost-effectiveness studies are needed to more definitively assess the safety and efficacy of this practice," they concluded.
These findings are promising considering infections such as CDI are among the most common complications affecting HSCT patients.